Pharmacologic treatments for covid-19 patients

Analyses are updated every Friday

Methods

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 283 treatment comparisons .

General characteristics of primary studies

Page: 1 / Sorted by: First Author
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
IRCT20201003048904N2
Abbasi F, SSRN (2021)
Full text
Commentary
Commentary
Public/non profit

Sitagliptin

Spironolactone

SITA+SPL

Standard care

RCT Patients with suspected or confirmed COVID-19 (unclear severity) admitted to 2 centers in Iran. N=0 N/A

Full description

IRCT20200328046886N1
Abbaspour Kasgari H, J Antimicrob Chemoth (2020)
Full text
Commentary
Public/non profit

SOF/DCV+RBV

Standard care

RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Iran. N=48
Some concerns
Details

Full description

ISRCTN21085622
Abbass S, J Med Virol (2021)
Full text
Commentary
Private

Sofosbuvir-Daclatasvir

SOF-RDV

Sofosbuvir-Daclatasvir

Standard care

Standard care

SOF-RDV

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Egypt N=120
Some concerns
Details

Full description

NCT04403555
Abd-Elsalam S, J Med Virol (2021)
Full text
Commentary
Not reported/unclear

Ivermectin

Standard care

RCT Patients with confirmed COVID-19 admitted to 2 centers in Egypt N=164
Some concerns
Details

Full description

NCT04353336
Abd-Elsalam S, Am J Trop Med Hyg (2020)
Full text
Commentary
Public/non profit

Hydroxychloroquine

Standard care

RCT Patients with COVID-19 (mild-severe) admitted to three university hospitals in Egypt. N=194
Some concerns
Details

Full description

NCT04447534
Abd-Elsalam S, Biol Trace Elem Res (2020)
Full text
Commentary

Hydroxychloroquine+Zinc

Hydroxychloroquine

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Egypt N=191
Some concerns
Details

Full description

NCT04345419
Abd-Elsalam S, Am J Trop Med Hyg (2021)
Full text
Commentary
Not reported/unclear

Remdesivir

Standard care

RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to two centres in Egypt N=209 N/A

Full description

NCT04753619
Abdulamir A, Ann Med Surg (2021)
Full text
Full text
Commentary
Commentary
No specific funding

Niclosamide

Standard care

RCT Outpatients and inpatients with confirmed COVID-19 (mild-moderate-severe) admitted or treated by 2 centers in Iraq N=150
Some concerns
Details

Full description

NCT04315948, EudraCT2020-000936-23
DisCoVeRy
Ader F, Lancet Infect Dis (2021)
Full text
Full text
Commentary
Public/non profit

Remdesivir

Standard care

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 48 centers in France (39), Belgium (3), Portugal (2), Austria (3), and Luxembourg (1). N=857
Some concerns
Details

Full description

NCT04315948
DisCoVeRy
Ader F, Clin Microbiol Infec (2021)
Full text
00259-7/fulltext Commentary
Commentary
Mixed

Lopinavir-Ritonavir

LPV/r+IFN beta-1a

Hydroxychloroquine

Lopinavir-Ritonavir

Lopinavir-Ritonavir

LPV/r+IFN beta-1a

Standard care

Standard care

Standard care

LPV/r+IFN beta-1a

Hydroxychloroquine

Hydroxychloroquine

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg N=603
Some concerns
Details

Full description